Login

Financial Snapshot

Revenue
TTM
$11.88M
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$164.1M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
1377.88%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$183.8M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$148.4M

Stock Price

Loading...
Market Cap: $468.86 Million

About Crescent Biopharma Inc

Crescent Biopharma Inc (NASDAQ: CBIO) is a biopharmaceutical company. The available filing excerpts from the 10-K filed 2026-02-26 (accession 000162828026011983) do not contain sufficient business description, revenue model, product, or operational detail to support a complete canonical description. No specific revenue figures, product names, pipeline assets, end markets, competitors, or geographic data are extractable from the provided excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: AIM ImmunoTech Inc Jasper Therapeutics Inc Oruka Therapeutics Inc Vistagen Therapeutics Inc Harpoon Therapeutics, Inc. Pasithea Therapeutics Corp Vicapsys Life Sciences, Inc. Spruce Biosciences, Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support